Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Blog Article

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM).Although recent data have demonstrated very promising results in clinical practice and trials, opheliasmuse.com some patients do not achieve a partial response, and ultimately all patients undergo progression.Dara exerts turbo air m3f72-3-n anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects.Deregulation of these pleiotropic mechanisms may cause development of Dara resistance.

Knowledge of this resistance may improve the therapeutic management of MM patients.